Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Portia Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

NCT07502417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ethinyl Estradiol + Levonorgestrel, ABBV-722
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196365
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 3 Interventional

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

NCT00128934
View directory record Official record
Conditions
Menstruation Disturbances, Premenstrual Syndrome
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Obesity, Oral Contraception, and Ovarian Suppression

NCT00827632
View directory record Official record
Conditions
Ovarian Suppression
Interventions
Low dose formulation, High dose formulation
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

NCT06657105
View directory record Official record
Conditions
Healthy Participants
Interventions
EE/LNG, Baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

NCT02922127
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Combined Oral Contraceptive Pill
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

NCT02641990
View directory record Official record
Conditions
Healthy Adult Premenopausal Female Volunteers
Interventions
ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

NCT00394771
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
DR-1031, Seasonale®, Portia®
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
567 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 19, 2026, 2:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantification of Immune Cells in Women Using Contraception (CHIC II)

NCT01873170
View directory record Official record
Conditions
HIV, Immune Cells (Mucosal and Systemic), Contraception
Interventions
levonorgestrel exposure, DMPA exposure, etonogestrel exposure, IUD insertion, subdermal contraceptive implant insertion
Drug · Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
View directory record Official record
Conditions
Healthy
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

NCT03630159
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel, Pembrolizumab
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

NCT01250210
View directory record Official record
Conditions
Ovulation Suppression
Interventions
levonorgestrel and ethinyl estradiol
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
11
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT07539090
View directory record Official record
Conditions
Healthy Participants
Interventions
Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

NCT06942936
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004, Itraconazole, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 19, 2026, 2:33 AM EDT
Not listed Phase 1 Interventional

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

NCT03557619
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Venetoclax, ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Detroit, Michigan • Lebanon, New Hampshire • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

NCT00117273
View directory record Official record
Conditions
Healthy
Interventions
Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE)
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

NCT01181479
View directory record Official record
Conditions
Contraception
Interventions
AG200-15 (cycles 1-13), Lessina crossover to AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
17 Years to 40 Years · Female only
Enrollment
1,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
80
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

NCT07074327
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 19, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

NCT06671405
View directory record Official record
Conditions
Dyslipidaemia
Interventions
AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 19, 2026, 2:33 AM EDT